Lamivudine: Positive Effects In Hepatitis B
BioChem Pharma's has announced results from a Phase II study of its antiviral lamivudine (3TC) in chronic hepatitis B patients which suggest that the agent can reduce viral DNA to undetectable levels. The data were presented at the annual meeting of the American Association for the Study of Liver Diseases in Chicago last week.
At a dose of 100-300mg/day, lamivudine reduced hepatitis B virus DNA to undetectable levels in all patients who received the drug. 32 patients were enrolled into the study from three study sites and received either 25mg/day, 100mg/day or 300mg/day lamivudine for three months and then followed up for six months thereafter. Reduction of HBV DNA was sustained throughout the follow-up period in six of 22 (27%) patients in the 100mg and 300mg group. Side effects of the treatment included headache, fatigue, nausea and abdominal pain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze